Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study

The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review

“…Significance Value p = 0.384 benefit- (Fig. 4) including six with statistical significance (Capra et al, 2020;Guaraldi et al, 2020;Gokhale et al, 2020;Rossotti et al, 2020;Somers et al, 2020;Potere et al, 2020).…”

“…Ip et al (2020),Eimer et al (2020) andPotere et al (2020) only analyzed patients who were already admitted into the ICU. A total of 61% and 44.8% of both cases and controls in Rojas-Marte et al (2020) and Roumier et al…”

COVID-19: pressure ulcers, pain and the cytokine storm

“…25 Anti-inflammatory medications and, specifically, medications causing IL-6 and TNF-α receptor blockade are therefore a natural target for treating COVID-19 and, in small scale clinical studies, these medications have shown the potential to reduce the risk of progression of the disease from severe to critical (and therefore the associated mortality). 26,27 In a recent Lancet paper, Robinson et al stated that there is hope that such IL-6/TNF-α receptor blockade-based medications will be able to reduce the inflammationdriven capillary leak in COVID-19 and thereby have a major positive impact on the need for ventilation and on mortality. 28 Interestingly, in the last few years, the author's group has put an emphasis on research on modulation of inflammation as a promising route for prevention and treatment of PUs, including MDRPUs, for example by means of polymeric membrane dressings.…”

Correspondence on ‘Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: case–control study’

“…We read with great interest the recent article by Potere et al using interleukin (IL)-6 receptor blockade with subcutaneous tocilizumab in SARS-CoV-2 COVID-19 pneumonia and hyperinflammatory syndrome. 1 A potential preventive or therapeutic effect of certain immunomodulatory therapies in COVID-19 has been hypothesised. Among them, corticosteroids, IL-6 or IL-1 antagonists have been reported and successfully used in severe COVID-19 and associated hyperinflammatory syndromes.…”

“…Among them, corticosteroids, IL-6 or IL-1 antagonists have been reported and successfully used in severe COVID-19 and associated hyperinflammatory syndromes. [1][2][3][4] The hyperinflammation observed in adult patients with severe COVID-19 resembles a cytokine release syndrome (CRS) associated with CD4 + and CD8 + T-cell lymphopaenia and increased cytokine levels, including IL-6, correlating with clinical severity. [5][6][7][8][9] In contrast to CRS, immune reconstitution inflammatory syndrome (IRIS) is an exaggerated inflammatory response driven by predominant CD4 + T helper cells that have been reported secondary to previous initiation of antiretroviral therapy (ART) when the immune system begins to recover following treatment with ART.…”